Director, Investor Relations

Immix Biopharma (Nasdaq: IMMX); Los Angeles (CA); On-site; USD 180,000 - 240,000; Full time

Job summary

Immix Biopharma, Inc. seeks a Director of Investor Relations to translate complex scientific and clinical data into compelling narratives for investors, analysts, and the financial press.

You will lead press releases, earnings filings, conferences, roadshows, and corporate presentations while ensuring regulatory compliance. You will develop and execute comprehensive investor communications strategies, build relationships with analysts and media, and guide messaging across the company's portfolio

Qualifications

• 7-9 years’ experience in investor relations, corporate communications, or media with a strong understanding of business needs and competitive challenges in the life science industry.
• Experience in the biotech industry in investor relations and corporate communications or as sell-side analyst.
• Proven written and verbal communication strength with the ability to tailor messages to a diverse set of audiences.
• Bachelor’s degree in life sciences, pharmacy, or a related field; advanced degree preferred.

Responsibilities

• Develop and execute a communications strategy with investors via quarterly filings, conference calls, investor conferences, and roadshows
• Ensure that there is effective and consistent execution on the corporate communications strategy to ensure optimal outreach to investors and analysts
• Lead, develop and execute a comprehensive, strategic communications strategy and tactical plan to achieve key investor relations objectives; evolve as needed
• Develop written materials, such as key messages, FAQs and talking points to effectively communicate the company’s positioning, decision, or program updates for conference calls and other investor/analysts events
• Leverage existing network and build strong relationships with analysts, investors, members of the press, influencers, and partners
• Partner with media, and external partners as needed to develop and execute campaigns, outreach programs, and monitor brand activity.
• Maintain a thorough understanding of our corporate strategy and the importance of each stakeholder segment to our corporate and scientific portfolio and messaging.
• Manage daily proactive and responsive communications for the company, including devising a crisis communications strategy and rapid response efforts

Skills

Investor relations experience

Corporate communications

Strong written and verbalcommunication

Strategic leadership

Startup/adaptive mindset

Education

Bachelor’s degree in life sciences, pharmacy, or a related field

Advanced degree preferred

Job description

The Director, Investor Relations ensures that the Company’s scientific and clinical development strategy and progress are clearly communicated to investors, analysts, media, and the broad financial community. The person in this role must translate complex technical data into investment-driving narratives. Key areas of responsibility include press releases, corporate website, quarterly earnings filings, organizing conferences/roadshows, optimizing the corporate presentation, communicating corporate milestones, and ensuring regulatory compliance.

Key Responsibilities

• Develop and execute a communications strategy with investors via quarterly filings, conference calls, investor conferences, and roadshows
• Ensure that there is effective and consistent execution on the corporate communications strategy to ensure optimal outreach to investors and analysts
• Lead, develop and execute a comprehensive, strategic communications strategy and tactical plan to achieve key investor relations objectives; evolve as needed
• Develop written materials, such as key messages, FAQs and talking points to effectively communicate the company’s positioning, decision, or program updates for conference calls and other investor/analysts events
• Leverage existing network and build strong relationships with analysts, investors, members of the press, influencers, and partners
• Partner with media, and external partners as needed to develop and execute campaigns, outreach programs, and monitor brand activity.
• Maintain a thorough understanding of our corporate strategy and the importance of each stakeholder segment to our corporate and scientific portfolio and messaging.
• Manage daily proactive and responsive communications for the company, including devising a crisis communications strategy and rapid response efforts

What We Look For

• 7-9 years’ experience in investor relations, corporate communications, or media with a strong understanding of business needs and competitive challenges in the life science industry.
• Experience in the biotech industry in investor relations and corporate communications or as sell-side analyst.
• Proven written and verbal communication strength with the ability to tailor messages to a diverse set of audiences
• Bachelor’s degree in life sciences, pharmacy, or a related field; advanced degree preferred.

Preferred

• Ability to lead discussions, attention to detail and strategic thinking.
• Collaborative leadership style.
• Track record of prioritizing and executing competing priorities in a fast-moving environment.
• Willingness to “roll-up your sleeves” managing a diverse set of objectives, shifting fluidly from strategy to execution consistent with a start-up environment.
• Agile and creative thinker in external communications; uses sound judgement.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non‑specific activation. NXC‑201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC‑201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC‑201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.